Table 6.
Factors significantly associated with treatment failure.
| Characteristic | OR | 95% CI | p Value |
|---|---|---|---|
| Antimicrobial resistance other than ESBL, MDR/XDR | 1.39 | 1.00, 1.93 | 0.051 |
| ESBL pathogens | 3.69 | 2.12–6.21 | <0.001 |
| MDR/XDR pathogens | 4.07 | 2.57, 6.36 | <0.001 |
| Age | 1.03 | 0.98, 1.07 | 0.21 |
| Male sex | 1.08 | 0.78, 1.48 | 0.65 |
| Recurrent UTI | 2.04 | 1.28, 3.16 | 0.002 |
| Antibiotic prophylaxis | 1.87 | 0.93, 3.56 | 0.064 |
| Antibiotic therapy in the previous 30 days | 1.75 | 1.12, 2.66 | 0.011 |
| Vescico-ureteral reflux | 1.17 | 0.79, 1.80 | 0.45 |
| Other urological malformations | 1.49 | 0.98, 2.22 | 0.055 |
| Pielectasis | 1.41 | 1.01, 1.96 | 0.045 |
| Nephromegaly | 2.85 | 1.01, 1.96 | <0.001 |
| Treatment with amoxicillin | 5.06 | 2.38, 10.2 | <0.001 |
| Treatment with amoxicillin/clavulanate | 1.67 | 1.20, 2.32 | 0.002 |
| Treatment with ampicillin + aminoglycosides | 0.99 | 0.64, 1.49 | 0.96 |
| Treatment with third-generation cephalosporins | 0.46 | 0.32, 0.65 | <0.001 |
| Treatment with third-generation cephalosporins + aminoglycosides | 0.77 | 0.32, 1.57 | 0.51 |
| Treatment with aminoglycosides | 1.20 | 0.28, 3.50 | 0.77 |
CI: confidence interval; ESBL: extended-spectrum beta-lactamase MDR: multidrug resistant; OR, odds ratio; XDR: extensively drug resistant.